Business Wire

PROCESS-SYSTEMS-ENTERPRI

22.4.2016 16:46:03 CEST | Business Wire | Press release

Share
PSE: Advanced Process Modelling Forum Gathers Process Industries in London

At the 5th Advanced Process Modelling (APM) Forum in London this week, companies from across the process industries presented on topics ranging from accelerating development of the next generation of drugs to identifying hundreds of millions of Euros in operational savings in natural gas production.

Organised and hosted by Process Systems Enterprise (PSE), providers of the gPROMS APM platform, the two-day conference is a key event for process industry organisations focused on creating sustainable value through the application of high-accuracy predictive process modelling and optimisation.

In the sessions on formulated products, aimed at the pharmaceuticals, food & beverage, consumer goods and specialty chemicals sectors, presentations from AstraZeneca, Danone, Eli Lilly, Roche, Saint-Gobain, and Solvay described how new ‘digital design’ techniques are improving drug product manufacture, including development of robust continuous manufacturing processes, and accelerating time-to-market for new formulations.

A key event was the preview of PSE’s forthcoming gPROMS FormulatedProductsTM environment for integrated design and optimisation of formulated products and their manufacturing processes. Developed in co-operation with specialists from several sectors, this allows scientists and engineers to screen formulations for end-user attributes, determine whether they can be manufactured efficiently, and then use the gPROMS platform's optimisation capabilities to optimise the whole formulation and manufacturing chain.

In the oil & gas, chemicals, petrochemical & refining sessions, where presenters included Bharat Petroleum, BP Exploration, DSM, Primetals, SABIC, SCG Chemicals, Shell, Sulzer, Velocys and Yara International, the focus was on large-scale optimisation applications capable of improving profit by tens or hundreds of millions of Euros. These included major new developments in oilfield optimisation capable of identifying millions of dollars a day in increased production, Shell's work on region-wide optimisation of natural gas processing facilities, Bharat Petroleum’s innovative work in real-time optimisation of refinery crude transition, and DSM’s operational optimisation of the utility systems supplying electricity and steam to large-scale industrial sites. SABIC described how model-based analysis helped reduce the time to screen anti-coking technologies for ethylene production from years to months.

PSE MD Costas Pantelides said, “A key focus of the conference has been the coming of age of equation-oriented (EO) process modelling tools. EO is a disruptive technology that for the first time makes it possible to optimise large-scale, complex process systems using high-fidelity models and apply techniques such as global system analysis to explore the design and operational space much more rapidly than previously possible. This is enabling companies to realise large gains in competitive advantage and dramatically accelerate innovation”.

Keynote speaker Peter Drogt of DSM, standing in for Dorus van der Linden, said that advanced process modelling is crucial technology for the organisation to accelerate innovation and quantify process decisions. A key reason for the company’s move to APM is the ability to have a single unified modelling platform across the process lifecycle.

Editors: www.psenterprise.com/news/pr160422.html

Contact:

Process Systems Enterprise
Kate Burness
+44-20-8563-0888
k.burness@psenterprise.com

Link:

ClickThru

Social Media:

https://www.facebook.com/pages/Process-Systems-Enterprise-Limited-PSE/194030330653358?ref=bookmarks

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 22:30:00 CEST | Press release

Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye